GlaxoSmithKline Recalls Nicorette Lozenges Due to Failed Specifications
GlaxoSmithKline is recalling specific lots of Nicorette lozenges because they failed quality specifications, including being overly thick, soft, and sub or superpotent.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The FDA classified this as a Class III recall, which is defined as unlikely to cause adverse health consequences. The issue involves quality control failures (potency and physical characteristics) rather than a high-risk pathogen or structural defect.
Plain-English summary
GlaxoSmithKline Consumer Healthcare is recalling specific lots of Nicorette (nicotine polacrilex) Lozenges Mini, 4 mg, Original Flavor. The affected products include 20-count and 81-count vials distributed nationwide in the United States. The recall involves approximately 189,900 20-count vials and 145,068 81-count vials.
The recall was initiated because the lozenges failed to meet quality specifications. Specifically, the affected lozenges were found to be overly thick, overly soft, and sub or superpotent. Subpotent lozenges contain less nicotine than labeled, while superpotent lozenges contain more.
Consumers who have purchased these specific lots should stop using the product and contact GlaxoSmithKline for a refund or replacement. The affected lot numbers and expiration dates are: 20-count vials Lot #14337 (exp 7/15), 14398 (exp 9/15), and 14510 (exp 9/15); 81-count vials Lot #14336 (exp 7/15), 14347 (exp 7/15), 14378 (exp 9/15), and 14563 (exp 9/15).
The recalled product
- Product
- NICORETTE (NICOTINE POLACRILEX)
- Brand
- NICORETTE
- Category
- Drug — OTC Nicotine Replacement
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (6)
- (20 ct) Lot #14337 (exp 7/15)
- 14398 (exp 9/15) & 14510 (exp 9/15)
- (81 ct) Lot #14336 (exp 7/15)
- 14347 (exp 7/15)
- 14378 (9/15)
- 14563 (exp 9/15)
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 10 recalled by GlaxoSmithKline Consumer Healthcare; dba-GlaxoSmithKline under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 10 products in this recall →Related recalls
Same brand · NICORETTE
- ModerateGlaxoSmithKline Recalls Nicorette Lozenges Due to Failed Specifications
FDA (Drugs) · 2014-04-30
- ModerateGlaxoSmithKline Recalls Nicorette Lozenges Due to Failed Specifications
FDA (Drugs) · 2014-04-30
- LowGlaxoSmithKline Recalls Nicorette Lozenges Due to Failed Specifications
FDA (Drugs) · 2014-04-30
Same manufacturer · GlaxoSmithKline Consumer Healthcare; dba-GlaxoSmithKline
See all →- ModerateGlaxoSmithKline Recalls Nicotine Lozenges Due to Failed Specifications
FDA (Drugs) · 2014-04-30
- LowGlaxoSmithKline Recalls Nicorette and Nicoderm CQ Products for Quality Failures
FDA (Drugs) · 2014-04-30
- LowGlaxoSmithKline Recalls Nicorette Lozenge and NicoDerm CQ Combination Pack
FDA (Drugs) · 2014-04-30
- ModerateGlaxoSmithKline Recalls Nicotine Lozenges Due to Failed Specifications
FDA (Drugs) · 2014-04-30
Same hazard · quality control
See all →- ModerateApotex Recalls Paxil Tablets for Failed Dissolution and Stability Testing
FDA (Drugs) · 2026-09-02
- ModerateDuoGlide Short-Term Dialysis Catheter recall due to deficient manufacturing
FDA (Devices) · 2026-07-08
- ModeratedirectCHECK whole blood control labeled with incorrect performance range
FDA (Devices) · 2026-06-24
- HighAmyloid plasma controls recalled over falsely elevated ratio results
FDA (Devices) · 2026-02-11
- HighpTau 217 plasma controls recalled over falsely elevated ratio results
FDA (Devices) · 2026-02-11